CNBC Reports Insurers and Doctors Disagree Over Use Of PCSK9 inhibitors

The new class of lipid lowering drugs, the  injectable drugs, PCSK9 inhibitors, reduce bad cholesterol when combined with statins, but they are expensive and therefore payment is often restricted by insurance companies.

https://www.cnbc.com/2017/09/06/americas-no-1-killer-heart-disease-at-center-of-drug-prices-battle.html

Share

Leave a Reply

Your email address will not be published. Required fields are marked *